New study finds triple-negative breast cancer tumors with an …
WEBApr 25, 2024 · A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative ...
WEBSep 15, 2024 · In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the...
Early-stage immuno prolongs OS in triple-negative breast cancer
WEB6 days ago · “The final overall survival (OS) data from the KEYNOTE-522 study represent some of the most significant results observed in the treatment of early breast cancer,” says Dr Carmen Criscitiello from the European Institute of Oncology, Milan, Italy, commenting on data reported in a Presidential Symposium at the ESMO Congress 2024 (Barcelona, 13 ...
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery …
WEBSep 15, 2024 · KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as …
Understanding triple-negative breast cancer and its treatment
WEBJan 3, 2024 · Triple-negative breast cancer, also called basal-like breast cancer, is a subtype that isn't affected by hormones or the HER2 gene. It grows rapidly, is more likely to spread beyond the breast before diagnosis and is …
Biology Behind New Drug Used to Treat Triple-Negative Breast Cancer ...
WEBWASHINGTON (July 17, 2023) — How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center who worked in collaboration …
Latest Research On Triple-Negative Breast Cancer | BCRF
WEBFeb 29, 2024 · Most recently, results from the pivotal CAPItello-290 trial led the FDA to approve capivasertib (Truqap®), the first-in-class AKT inhibitor for treating hormone receptor–positive/HER2-negative breast cancer. Further testing will be needed to assess its efficacy in TNBC.
FDA Approves New Therapy for Triple Negative Breast Cancer …
WEBApr 22, 2020 · FDA granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread.
Pembrolizumab for Advanced Triple-Negative Breast Cancer
WEBAugust 9, 2022, by Edward Winstead. Adding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer than if they received chemotherapy alone, new results from a …
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
WEBJul 20, 2022 · Among patients with advanced triple-negative breast cancer whose tumors expressed PD-L1 with a CPS of 10 or more, the addition of pembrolizumab to chemotherapy resulted in significantly...